05:59 AM EDT, 08/22/2022 (MT Newswires) -- Hainan Poly Pharm (SHE:300630) has won approval from the US Food and Drug Administration to market a drug for the treatment of complex skin diseases for adults and pediatric patients, according to a filing on Monday.
The Chinese drugmaker's daptomycin for injection is also designed to treat staphylococcus aureus in adult patients, as well as bacterial bloodstream infections.
The drug is marketed under the brand name Cubicin.
Price (RMB): ¥28.81, Change: ¥+0.76, Percent Change: +2.71%